

Mackenzie US Mid Cap Opportunities Fund Series A

US Equity

Compound Annualized Returns‡	10/31/2024
1 Month	
3 Months	
Year-to-date	9.2%
1 Year	
2 Years	10.2%
3 Years	0.5%
Since inception (May. 2020)	8.0%
Regional Allocation	09/30/2024
CASH & EQUIVALENTS	
Cash & Equivalents	4.6%
OVERALL	05 40/
United States	95.4%
Sector Allocation	09/30/2024
Health Care	31.0%
Industrials	25.2%
Information Technology	25.2%
Financials	8.3%
Real Estate	4.7%
Cash & Equivalents	4.6%
Consumer Discretionary	1.0%
Portfolio Managers	

Calendar Year Returns (%) 10/31/2024

′23



SERIES	FREQUENCY	AMOUNT	DATE
A	Annually	0.1021	12/23/2022
F	Annually	0.1224	12/23/2022
T8	Monthly	0.0928	10/18/2024
PW	Annually	0.1069	12/23/2022
	,		
Fund Cod	des:		

Fund Codes:				
SERIES (C\$)	PREFIX	FE	BE *	LL3 *
A	MFC	8108	8109	8110
F	MFC	8113	_	
T8	MFC	8130	8131	8132
PW	MFC	8119	_	
Additional fund series available at mackenzieinvestments.com/fundcodes				

\$1.8 billion

A: 2.55% F: 1.05%

A: 2.00% F: 0.80%

Russell Mid Cap Total Return Index

C\$13.70

Mackenzie Growth Team Phil Taller, John Lumbers

Major Holdings Represent 48.6% of the fund ExlService Holdings Inc 5.7% Bio-Techne Corp 5.4% Akamai Technologies Inc 5.2% CoStar Group Inc 4.7% Dexcom Inc 4 7% SS&C Technologies Holdings Inc 4.7% Charles River Laboratories International Inc 4.6% Maximus Inc 4.6% Hologic Inc 4.5% 4.4% Cirrus Logic Inc

TOTAL NUMBER OF EQUITY HOLDINGS: 30

Fund Risk Measures (3 year)			10/31/2024
Annual Std Dev	14.88	Beta	0.91
B'mark Annual Std	15.29	R-squared	0.87
Dev.		Sharpe Ratio	-0.21
Alpha	-6.85		

Source: Mackenzie Investments

Major Holdings***

Why Invest in this fund?

09/30/2024

Key Fund Data

Total Fund Assets: NAVPS (10/31/2024):

MER (as of Mar. 2024):

Management Fee:

Benchmark**:

- Access mid cap stocks that can offer a unique risk-return 'sweet spot' between fast-growing small businesses and mature large companies.
- Leverage our team's investment edge to discern between ideas and real business opportunities.
- Seek alpha in an under-researched universe of US mid caps with a concentrated portfolio of high-quality, innovative, secular growth businesses.

Risk Tolerance

LOW MEDICINI HIGH	LOW	MEDIUM	HIGH
-------------------	-----	--------	------



Effective June 1, 2022, the redemption charge purchase option, and the low-load purchase option are no longer available for purchase, including those made through systematic purchase plans such as preauthorized contribution plans. Switching from securities of a Mackenzie Fund previously purchased under the redemption charge or low-load purchase options to securities of another Mackenzie Fund, under the same purchase option, will continue to be available until such redemption schedules expire.

The Russell Midcap Index (Net Return) measures the performance of the 800 smallest companies in the Russell 1000 Index.

The major holdings of the Fund may, but do not necessarily, represent the largest holdings of the Fund. Rather, the major holdings are selected for their overall significance in evaluating the investment portfolio.
Commissions, trailing commissions, management fees, and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return the historical annual compounded total returns as of October 31, 2024 including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution, or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. Standard deviation provides a measure of the variability of returns that have occurred relative to the average return. The higher the standard deviation, the greater is the range of returns that has been experienced. Standard deviation is commonly used as a measure of risk.